Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sells $1,012,890.42 in Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Francis Lo sold 44,838 shares of the stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $22.59, for a total value of $1,012,890.42. Following the sale, the insider owned 230,713 shares of the company’s stock, valued at approximately $5,211,806.67. This represents a 16.27% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Francis Lo also recently made the following trade(s):

• On Wednesday, July 1st, Francis Lo sold 51,004 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $22.45, for a total value of $1,145,039.80.
• On Thursday, June 4th, Francis Lo sold 39,741 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $17.49, for a total value of $695,070.09.
• On Wednesday, April 8th, Francis Lo sold 22,564 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $15.07, for a total value of $340,039.48.

Adaptive Biotechnologies Price Performance

Shares of Adaptive Biotechnologies stock opened at $20.16 on Thursday. The firm has a market cap of $3.23 billion, a price-to-earnings ratio of -61.09 and a beta of 2.07. Adaptive Biotechnologies Corporation has a 52-week low of $9.96 and a 52-week high of $22.80. The stock has a 50-day simple moving average of $16.50 and a 200-day simple moving average of $15.96.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.03. The firm had revenue of $70.87 million for the quarter, compared to the consensus estimate of $61.03 million. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.The firm’s revenue was up 35.1% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.20) earnings per share. As a group, equities research analysts predict that Adaptive Biotechnologies Corporation will post -0.47 earnings per share for the current year.

Institutional Investors Weigh In On Adaptive Biotechnologies

Hedge funds have recently bought and sold shares of the company. AQR Capital Management LLC increased its stake in shares of Adaptive Biotechnologies by 45.8% in the first quarter. AQR Capital Management LLC now owns 310,272 shares of the company’s stock worth $2,265,000 after purchasing an additional 97,444 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Adaptive Biotechnologies by 4.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 68,830 shares of the company’s stock worth $511,000 after purchasing an additional 2,914 shares during the period. Caxton Associates LLP acquired a new position in Adaptive Biotechnologies in the 1st quarter valued at approximately $93,000. New York State Common Retirement Fund raised its stake in shares of Adaptive Biotechnologies by 39.2% in the second quarter. New York State Common Retirement Fund now owns 47,258 shares of the company’s stock valued at $551,000 after purchasing an additional 13,300 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its position in shares of Adaptive Biotechnologies by 728.8% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 379,120 shares of the company’s stock valued at $4,417,000 after acquiring an additional 333,379 shares in the last quarter. 99.17% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the stock. Morgan Stanley cut their price target on shares of Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Monday, April 20th. JPMorgan Chase & Co. reduced their price target on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. BTIG Research reissued a “buy” rating and set a $22.00 price objective on shares of Adaptive Biotechnologies in a report on Wednesday, June 17th. Finally, Guggenheim raised their price objective on Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Adaptive Biotechnologies has an average rating of “Moderate Buy” and an average target price of $20.50.

Key Adaptive Biotechnologies News

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Negative Sentiment: Harlan Robins sold 386,240 shares of Adaptive Biotechnologies, a transaction worth about $8.5 million, which is the most notable insider sale and may signal caution to investors. Article Title
• Negative Sentiment: Susan Bobulsky sold 487 shares, adding to a pattern of insider selling at Adaptive Biotechnologies. Article Title
• Negative Sentiment: Francis Lo sold 44,838 shares and separately sold another 51,004 shares, reinforcing the recent insider selling trend in ADPT. Article Title
• Neutral Sentiment: Recent filings note that these sales were made under pre-arranged 10b5-1 trading plans, which can reduce the significance of the transactions compared with discretionary selling.
• Positive Sentiment: Adaptive Biotechnologies previously posted better-than-expected quarterly results, including revenue growth of 35.1% year over year and EPS that beat estimates, which may help limit downside pressure.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.